CN Patent

CN113905744A — 经修饰的间隙子寡核苷酸及其使用方法

Assigned to Aligos Therapeutics Inc · Expires 2022-01-07 · 4y expired

What this patent protects

本公开包含反义寡核苷酸，包含间隙子反义寡核苷酸；以及制备和使用方法，例如针对HBV。

USPTO Abstract

本公开包含反义寡核苷酸，包含间隙子反义寡核苷酸；以及制备和使用方法，例如针对HBV。

Drugs covered by this patent

eplontersen-sodium (EPLONTERSEN SODIUM)

Patent Metadata

Patent number: CN113905744A
Jurisdiction: CN
Classification: —
Expires: 2022-01-07
Drug substance claim: No
Drug product claim: No
Assignee: Aligos Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.